{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:45:19Z","timestamp":1760100319842,"version":"3.37.3"},"reference-count":39,"publisher":"Wiley","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"funder":[{"DOI":"10.13039\/501100001824","name":"Grantov\u00e1 Agentura Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["305\/08\/1704"],"award-info":[{"award-number":["305\/08\/1704"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mediators of Inflammation"],"published-print":{"date-parts":[[2010]]},"abstract":"<jats:p>To evaluate the effect of a cyclooxygenase 2 inhibitor, celecoxib (CEL), on bladder cancer inhibition in a rat model, when used as preventive versus as curative treatment. The study comprised 52 male Wistar rats, divided in 5 groups, during a 20-week protocol: control: vehicle, carcinogen: 0.05% of<jats:italic>N<\/jats:italic>-butyl-<jats:italic>N<\/jats:italic>-(4-hydroxybutyl) nitrosamine (BBN), CEL: 10\u2009mg\/kg\/day of the selective COX-2 inhibitor Celebrex, preventive CEL (CEL+BBN-P), and curative CEL (BBN+CEL-C) groups. Although tumor growth was markedly inhibited by the preventive application of CEL, it was even aggravated by the curative treatment. The incidence of gross bladder carcinoma was: control 0\/8(0%), BBN 13\/20(65%), CEL 0\/8(0%), CEL+BBN-P 1\/8(12.5%), and BBN+CEL-C 6\/8(75%). The number and volume of carcinomas were significantly lower in the CEL+BBN-P versus BBN, accompanied by an ample reduction in hyperplasia, dysplasia, and papillary tumors as well as COX-2 immunostaining. In spite of the reduction of tumor volumes in the curative BBN+CEL-C group, tumor malignancy was augmented. An anti-inflammatory and antioxidant profile was encountered only in the group under preventive treatment. In conclusion, preventive, but not curative, celecoxib treatment promoted a striking inhibitory effect on bladder cancer development, reinforcing the potential role of chemopreventive strategies based on cyclooxygenase 2 inhibition.<\/jats:p>","DOI":"10.1155\/2010\/380937","type":"journal-article","created":{"date-parts":[[2011,2,13]],"date-time":"2011-02-13T14:33:50Z","timestamp":1297607630000},"page":"1-11","source":"Crossref","is-referenced-by-count":10,"title":["Preventive but Not Curative Efficacy of Celecoxib on Bladder Carcinogenesis in a Rat Model"],"prefix":"10.1155","volume":"2010","author":[{"given":"Jos\u00e9","family":"Sereno","sequence":"first","affiliation":[{"name":"Institute of Pharmacology & Experimental Therapeutics, IBILI, Medicine Faculty, Sub-Unit 1 (Polo III), Coimbra University, 3000-354 Coimbra, Portugal"}]},{"given":"Belmiro","family":"Parada","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology & Experimental Therapeutics, IBILI, Medicine Faculty, Sub-Unit 1 (Polo III), Coimbra University, 3000-354 Coimbra, Portugal"},{"name":"Department of Urology & Renal Transplantation, Coimbra University Hospital, 3000-075 Coimbra, Portugal"}]},{"given":"Fl\u00e1vio","family":"Reis","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology & Experimental Therapeutics, IBILI, Medicine Faculty, Sub-Unit 1 (Polo III), Coimbra University, 3000-354 Coimbra, Portugal"},{"name":"Institute for Molecular and Cellular Biology, Porto University, 4150 Porto, Portugal"}]},{"given":"Fernanda X.","family":"Cunha","sequence":"additional","affiliation":[{"name":"Service of Anatomic Pathology, Coimbra University Hospital, 3000-075 Coimbra, Portugal"}]},{"given":"Edite","family":"Teixeira-Lemos","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology & Experimental Therapeutics, IBILI, Medicine Faculty, Sub-Unit 1 (Polo III), Coimbra University, 3000-354 Coimbra, Portugal"}]},{"given":"Patr\u00edcia","family":"Garrido","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology & Experimental Therapeutics, IBILI, Medicine Faculty, Sub-Unit 1 (Polo III), Coimbra University, 3000-354 Coimbra, Portugal"}]},{"given":"Rui","family":"Pinto","sequence":"additional","affiliation":[{"name":"Pharmacology & Pharmacotoxicology Unit, Pharmacy School of Lisbon, 1649-003 Lisboa, Portugal"}]},{"given":"Petronila","family":"Rocha-Pereira","sequence":"additional","affiliation":[{"name":"Institute for Molecular and Cellular Biology, Porto University, 4150 Porto, Portugal"},{"name":"Research Centre for Health Sciences, Beira Interior University, 6201-001 Covilh\u00e3, Portugal"}]},{"given":"Paula","family":"Neto","sequence":"additional","affiliation":[{"name":"Service of Anatomic Pathology, Coimbra University Hospital, 3000-075 Coimbra, Portugal"}]},{"given":"Jos\u00e9","family":"Ruivo","sequence":"additional","affiliation":[{"name":"Service of Anatomic Pathology, Coimbra University Hospital, 3000-075 Coimbra, Portugal"}]},{"given":"Paulo","family":"Rodrigues-Santos","sequence":"additional","affiliation":[{"name":"Immunology & Oncology Laboratory, Centre for Neuroscience and Cell Biology, 3004-517 Coimbra, Portugal"}]},{"given":"Sara","family":"Nunes","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology & Experimental Therapeutics, IBILI, Medicine Faculty, Sub-Unit 1 (Polo III), Coimbra University, 3000-354 Coimbra, Portugal"}]},{"given":"Alfredo","family":"Mota","sequence":"additional","affiliation":[{"name":"Department of Urology & Renal Transplantation, Coimbra University Hospital, 3000-075 Coimbra, Portugal"}]},{"given":"Arnaldo","family":"Figueiredo","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology & Experimental Therapeutics, IBILI, Medicine Faculty, Sub-Unit 1 (Polo III), Coimbra University, 3000-354 Coimbra, Portugal"},{"name":"Department of Urology & Renal Transplantation, Coimbra University Hospital, 3000-075 Coimbra, Portugal"}]},{"given":"Frederico","family":"Teixeira","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology & Experimental Therapeutics, IBILI, Medicine Faculty, Sub-Unit 1 (Polo III), Coimbra University, 3000-354 Coimbra, Portugal"},{"name":"Institute for Molecular and Cellular Biology, Porto University, 4150 Porto, Portugal"}]}],"member":"311","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.07.062"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl498"},{"issue":"10","key":"3","doi-asserted-by":"crossref","first-page":"RA311","DOI":"10.12659\/MSM.430336","volume":"11","year":"2005","journal-title":"Medical Science Monitor"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05249.x"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eursup.2008.04.001"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.12.031"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2006.09.028"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000043638.89552.ed"},{"issue":"2","key":"9","first-page":"145","volume":"25","year":"2006","journal-title":"Journal of Experimental and Clinical Cancer Research"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1159\/000108298"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2008.11.006"},{"key":"12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/1-4020-5688-5_4","volume":"42","year":"2007","journal-title":"Sub-Cellular Biochemistry"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2044.2000.01271.x"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2009.03.002"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1097\/00008469-200608000-00005"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2431050658"},{"issue":"1, supplement","key":"17","first-page":"S21","volume":"8","year":"1999","journal-title":"European Journal of Cancer Prevention"},{"issue":"12","key":"18","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1093\/carcin\/20.12.2305","volume":"20","year":"1999","journal-title":"Carcinogenesis"},{"issue":"6","key":"19","first-page":"2424","volume":"6","year":"2000","journal-title":"Clinical Cancer Research"},{"issue":"3","key":"20","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0002-9440(10)64033-3","volume":"158","year":"2001","journal-title":"American Journal of Pathology"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-3567"},{"issue":"17","key":"22","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.4161\/cbt.8.17.9199","volume":"8","year":"2009","journal-title":"Cancer Biology and Therapy"},{"issue":"1","key":"23","first-page":"81","volume":"67","year":"1976","journal-title":"Gann, The Japanese Journal of Cancer Research"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1016\/S1570-9124(03)00023-0"},{"first-page":"29","volume-title":"Tumors of the urinary system: non-invasive urothelial neoplasias","year":"2004","key":"25"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.12.011"},{"issue":"3","key":"27","first-page":"1","volume":"67","year":"2001","journal-title":"Anales de la Real Academia de Farmacia"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1006\/abio.1996.0292"},{"issue":"20","key":"29","first-page":"5599","volume":"60","year":"2000","journal-title":"Cancer Research"},{"issue":"3","key":"30","first-page":"247","volume":"59","year":"2007","journal-title":"Pharmacological Reports"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.15.11397"},{"issue":"8","key":"32","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/jnci\/94.8.585","volume":"94","year":"2002","journal-title":"Journal of the National Cancer Institute"},{"issue":"3","key":"33","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0022-5347(05)67321-1","volume":"164","year":"2000","journal-title":"Journal of Urology"},{"issue":"9","key":"34","first-page":"3503","volume":"9","year":"2003","journal-title":"Clinical Cancer Research"},{"key":"35","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2005.11.014"},{"key":"36","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23192"},{"key":"37","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-4-48"},{"key":"38","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-010-9229-0"},{"issue":"2","key":"39","first-page":"293","volume":"60","year":"2000","journal-title":"Cancer Research"}],"container-title":["Mediators of Inflammation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/mi\/2010\/380937.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/mi\/2010\/380937.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/mi\/2010\/380937.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,19]],"date-time":"2017-06-19T15:44:15Z","timestamp":1497887055000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/mi\/2010\/380937\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":39,"alternative-id":["380937","380937"],"URL":"https:\/\/doi.org\/10.1155\/2010\/380937","relation":{},"ISSN":["0962-9351","1466-1861"],"issn-type":[{"type":"print","value":"0962-9351"},{"type":"electronic","value":"1466-1861"}],"subject":[],"published":{"date-parts":[[2010]]}}}